The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Antipsychotic drugs are limited in their efficacy by the relatively poor response of negative and cognitive symptoms of schizophrenia as well as by the substantial variability in response between patients. Pharmacogenetic studies have sought to identify the genetic factors that underlie the individual variability in response to treatment, with a past emphasis on dopamine and serotonin receptors as candidate genes. Few studies have separated effects on positive and negative symptoms, despite the established differences in response to drug treatment between these syndromes. Where this has been done most findings are consistent with the conclusion that dopamine receptor polymorphisms relate to positive symptom response, while negative symptom improvement is influenced by polymorphisms of genes involved in 5-HT neurotransmission. A wide range of polymorphisms in other candidate genes have been investigated, with some positive findings in those genes associated with glutamatergic transmission and/or risk factors for schizophrenia. However, there remains a lack of good replicated findings; furthermore there is little evidence to support drug-specific genetic associations with treatment response. While most past studies focused on single candidate genes, technology now permits genome-wide association studies with response to antipsychotics. Although not without major limitations, these “hypothesis-free” approaches are beginning to identify further important risk factors for treatment response. Again there is little consistency between various studies, although some of the polymorphisms identified are in genes involved in neurodevelopment, which is increasingly being recognized as important in the pathophysiology of schizophrenia.
Abstract
Antipsychotic drugs are limited in their efficacy by the relatively poor response of negative and cognitive symptoms of schizophrenia as well as by the substantial variability in response between patients. Pharmacogenetic studies have sought to identify the genetic factors that underlie the individual variability in response to treatment, with a past emphasis on dopamine and serotonin receptors as candidate genes. Few studies have separated effects on positive and negative symptoms, despite the established differences in response to drug treatment between these syndromes. Where this has been done most findings are consistent with the conclusion that dopamine receptor polymorphisms relate to positive symptom response, while negative symptom improvement is influenced by polymorphisms of genes involved in 5-HT neurotransmission. A wide range of polymorphisms in other candidate genes have been investigated, with some positive findings in those genes associated with glutamatergic transmission and/or risk factors for schizophrenia. However, there remains a lack of good replicated findings; furthermore there is little evidence to support drug-specific genetic associations with treatment response. While most past studies focused on single candidate genes, technology now permits genome-wide association studies with response to antipsychotics. Although not without major limitations, these “hypothesis-free” approaches are beginning to identify further important risk factors for treatment response. Again there is little consistency between various studies, although some of the polymorphisms identified are in genes involved in neurodevelopment, which is increasingly being recognized as important in the pathophysiology of schizophrenia.
참고문헌 (59)
- Cipriani A., "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis", Lancet, 378, pp.1306~1315 (2011)
- Vojvoda D., "Monozygotic twins concordant for response to clozapine", Lancet, 347, pp.61~ (1996)
- Mata I., "Olanzapine: concordant response in monozygotic twins with schizophrenia", Br J Psychiatry, 178, pp.86~ (2001)
- Reynolds GP., "The impact of pharmacogenetics on the development and use of antipsychotic drugs", Drug Discov Today, 12, pp.953~959 (2007)
- Lieberman JA., "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Neill JC., "Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism", Pharmacol Ther, 128, pp.419~432 (2010)
- Meltzer HY., "The role of serotonin receptors in the action of atypical antipsychotic drugs", Curr Opin Pharmacol, 11, pp.59~67 (2011)
- Reynolds GP., "Pharmacogenetics of schizophrenia", Expert Opin Pharmacother, 7, pp.1429~1440 (2006)
- Malhotra AK., "Pharmacogenetics of psychotropic drug response", Am J Psychiatry, 161, pp.780~796 (2004)
- Zhang JP., "D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis", Am J Psychiatry, 167, pp.763~772 (2010)
- Hwang R., "Effect of dopamine D3 receptor gene polymorphisms and clozapine tr-eatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant", Pharmacogenomics J, 10, pp.200~218 (2010)
- Xuan J., "Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone resp-onse: a pharmacogenetic study", Neuropsychopharmacology, 33, pp.305~311 (2008)
- Xu MQ., "BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population", Pharmacogenet Genomics, 18, pp.449~457 (2008)
- Zhang A., "Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study", Pharmacogenomics, 8, pp.1337~1345 (2007)
- Serretti A., "HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies", Curr Med Chem, 14, pp.2053~2069 (2007)
- Benmessaoud D., "Excess of transmission of the G allele of the -1438A", G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics, 2008, pp.8, 40~
- Lesch KP., "Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region", Science, 274, pp.1527~1531 (1996)
- Dolzan V., "Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1562~1566 (2008)
- Wang L., "Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients", Neurosci Lett, 414, pp.1~4 (2007)
- Lee HY., "No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with ch-aracteristics and treatment response to atypical antipsychotic agents in schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.276~280 (2009)
- Mossner R., "Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia", Pharmacogenet Genomics, 19, pp.91~94 (2009)
- Reynolds GP., "Effect of 5-HT1A receptor gene polymorphism on negative and depressive symp-tom response to antipsychotic treatment of drug-naive psychotic patients", Am J Psychiatry, 163, pp.1826~1829 (2006)
- Wang L., "The --1019 C", G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients, 2008, pp.22, 904~909
- Hu XZ., "Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder", Am J Hum Genet, 78, pp.815~826 (2006)
- Lemonde S., "Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide", J Neurosci, 23, pp.8788~8799 (2003)
- Vazquez-Bourgon J., "Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis", Psychiatry Res, 175, pp.189~194 (2010)
- Adams DH., "Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder", Hum Psychopharmacol, 23, pp.267~274 (2008)
- Meary A., "Ph-armacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene", Am J Med Genet B Neu-ropsychiatr Genet, 147, pp.491~494 (2008)
- Schuhmacher A., "Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia", Pharmacogenet Genomics, 19, pp.843~851 (2009)
- Silver H., "Selective serotonin re-uptake inhibitor augmentation in the tr-eatment of negative symptoms of schizophrenia", Expert Opin Pharma-cother, 5, pp.2053~2058 (2004)
- Bertolino A., "COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia", Schizophr Res, 95, pp.253~255 (2007)
- Fijal BA., "Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia", Pharmacogenomics J, 9, pp.311~318 (2009)
- Weickert TW., "Catechol-O-methyltransferase val108", 158met genotype predicts working memory response to antipsychotic medications, 2004, pp.56, 677~682
- Bishop JR., "Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment", Schizophr Res, 77, pp.253~260 (2005)
- Bishop JR., "Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia" (2011), Hum Psychopharmacol
- Zuo L., "The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation", Pharmacogenet Genomics, 19, pp.437~446 (2009)
- Mossner R., "The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms" (2011), Eur Arch Psychiatry Clin Neurosci
- Lemonde S., "Association of the C (-1019)G 5-HT1A functional promoter polymorphism with antidepressant response", Int J Neuropsychopharmacol, 7, pp.501~506 (2004)
- Goldberg TE., "The serotonin transporter gene and disease modification in psychosis: evidence for systematic differences in allelic directionality at the 5-HTTLPR locus", Schizophr Res, 111, pp.103~108 (2009)
- Tollefson GD., "The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomiz-ed comparison of olanzapine and risperidone", Biol Psychiatry, 46, pp.365~373 (1999)
- Reynolds GP., "Receptor mechanisms in the treatment of schizophrenia", J Psychopharmacol, 18, pp.340~345 (2004)
- Arranz MJ., "Pharmacogenetic prediction of clozapine response", Lancet, 355, pp.1615~1616 (2000)
- Parsons MJ., "The -1438A", G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity, 2004, pp.56, 406~410
- Arranz MJ., "Pharmacogenetics of response to antipsychotics in patients with schizophrenia", CNS Drugs, 25, pp.933~969 (2011)
- Zhang JP., "Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction", Expert Opin Drug Metab To-xicol, 7, pp.9~37 (2011)
- Muller DJ., "Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia", Eur Neuropsychopharmacol, 15, pp.525~531 (2005)
- Anttila S., "Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach", BMC Psychiatry, 7, pp.22~ (2007)
- Kohlrausch FB., "G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics", Pharmacogenomics, 9, pp.1429~1436 (2008)
- Need AC., "Ph-armacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis", Eur J Hum Genet, 17, pp.946~957 (2009)
- Kantrowitz JT., "N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?", Brain Res Bull, 83, pp.108~121 (2010)
- Tamminga CA., "The neurobiology of cognition in schizophrenia", J Clin Psychiatry, 67, pp.9~13 (2006)
- McClay JL., "Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics", Mol Psychiatry, 16, pp.76~85 (2011)
- McClay JL., "Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia", Neuropsychopharmacology, 36, pp.616~626 (2011)
- Webb BT., "Model-based gene selection shows engrailed 1 is associated with antipsychotic response", Pharmacogenet Genomics, 18, pp.751~759 (2008)
- Spellmann I., "Ho-mer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients", J Psychiatr Res, 45, pp.234~241 (2011)
- Ikeda M., "Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches", Biol Psychiatry, 67, pp.263~269 (2010)
- Lavedan C., "Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study", Mol Psychiatry, 14, pp.804~819 (2009)
- Volpi S., "Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia", J Clin Psychiatry, 70, pp.801~809 (2009)
- Fijal BA., "Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone" (2011), J Clin Psychiatry